Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPETITION: Intratumoral Ad-SGE-REIC-NS for Recurrent Glioblastoma
jRCT2063250105Not yet recruiting
- Sponsor
- n.a.
- Start
- Jul 2026
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of Ad-SGE-REIC-NS in glioblastoma (GBM), sponsored by n.a. Primary endpoints: Two-year overall survival rate and Safety evaluation (adverse events and device deficiencies). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
Ad-SGE-REIC-NS
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on jRCT2063250105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2063250105.